Co-Diagnostics, Inc. Common Stock (CODX) - Total Assets
Based on the latest financial reports, Co-Diagnostics, Inc. Common Stock (CODX) holds total assets worth $21.50 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore CODX operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Co-Diagnostics, Inc. Common Stock - Total Assets Trend (2014–2025)
This chart illustrates how Co-Diagnostics, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See Co-Diagnostics, Inc. Common Stock (CODX) shareholders funds for net asset value and shareholders' equity analysis.
Co-Diagnostics, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Co-Diagnostics, Inc. Common Stock's total assets of $21.50 Million consist of 55.3% current assets and 44.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 48.0% |
| Accounts Receivable | $190.38K | 0.8% |
| Inventory | $992.40K | 4.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $7.22 Million | 29.2% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Co-Diagnostics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CODX market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Co-Diagnostics, Inc. Common Stock's current assets represent 55.3% of total assets in 2025, a decrease from 85.6% in 2014.
- Cash Position: Cash and equivalents constituted 48.0% of total assets in 2025, down from 82.5% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 29.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 29.2% of total assets.
Co-Diagnostics, Inc. Common Stock Competitors by Total Assets
Key competitors of Co-Diagnostics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩497.94 Billion |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.71 Billion |
|
Stratec SE
XETRA:SBS
|
Germany | €443.38 Million |
|
T&R Biofab Co. Ltd
KQ:246710
|
Korea | ₩83.86 Billion |
|
Hironic Co. Ltd
KQ:149980
|
Korea | ₩80.01 Billion |
|
Novacyt
PA:ALNOV
|
France | €40.28 Million |
|
HeraMED Limited
F:1I4
|
Germany | €1.49 Million |
|
Implanet SA
PA:ALIMP
|
France | €18.45 Million |
Co-Diagnostics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.28 | 4.43 | 19.10 |
| Quick Ratio | 2.09 | 4.23 | 18.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $5.50 Million | $18.45 Million | $85.59 Million |
Co-Diagnostics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Co-Diagnostics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.30 |
| Latest Market Cap to Assets Ratio | 0.21 |
| Asset Growth Rate (YoY) | -61.3% |
| Total Assets | $24.74 Million |
| Market Capitalization | $5.31 Million USD |
Valuation Analysis
Below Book Valuation: The market values Co-Diagnostics, Inc. Common Stock's assets below their book value (0.21x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Co-Diagnostics, Inc. Common Stock's assets decreased by 61.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Co-Diagnostics, Inc. Common Stock (2014–2025)
The table below shows the annual total assets of Co-Diagnostics, Inc. Common Stock from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $24.74 Million | -61.34% |
| 2024-12-31 | $64.00 Million | -32.86% |
| 2023-12-31 | $95.32 Million | -22.56% |
| 2022-12-31 | $123.09 Million | -23.09% |
| 2021-12-31 | $160.03 Million | +124.65% |
| 2020-12-31 | $71.24 Million | +3115.65% |
| 2019-12-31 | $2.22 Million | +42.63% |
| 2018-12-31 | $1.55 Million | -66.69% |
| 2017-12-31 | $4.66 Million | +259.80% |
| 2016-12-31 | $1.30 Million | +249.35% |
| 2015-12-31 | $370.93K | +42.75% |
| 2014-12-31 | $259.85K | -- |
About Co-Diagnostics, Inc. Common Stock
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provide… Read more